R1	Has_value Arg1:T3 Arg2:T4	
R2	Subsumes Arg1:T1 Arg2:T2	
R3	Subsumes Arg1:T2 Arg2:T3	
R4	AND Arg1:T5 Arg2:T6	
R5	Has_value Arg1:T7 Arg2:T8	
R6	Has_qualifier Arg1:T13 Arg2:T12	
R7	Has_qualifier Arg1:T11 Arg2:T10	
R8	AND Arg1:T9 Arg2:T7	
*	OR T9 T11 T13
*	OR T15 T16
R9	Has_value Arg1:T15 Arg2:T17	
*	OR T14 T15
R10	Has_index Arg1:T23 Arg2:T24	
*	OR T21 T22
*	OR T19 T20
R11	Has_mood Arg1:T19 Arg2:T21	
R12	Has_temporal Arg1:T19 Arg2:T23	
R13	Has_mood Arg1:T32 Arg2:T31	
*	OR T27 T28 T29 T34
*	OR T30 T32
R14	Has_temporal Arg1:T27 Arg2:T30	
*	OR T48 T47
R15	Has_qualifier Arg1:T48 Arg2:T46	
R16	Has_qualifier Arg1:T48 Arg2:T45	
*	OR T43 T44
R17	Has_qualifier Arg1:T43 Arg2:T42	
*	OR T39 T43 T48 T41 T40
R18	Has_index Arg1:T55 Arg2:T56	
*	OR T51 T53 T52 T54
R19	Has_temporal Arg1:T51 Arg2:T55	
R20	Has_index Arg1:T63 Arg2:T64	
*	OR T62 T61
*	OR T58 T59 T60
R21	Has_temporal Arg1:T62 Arg2:T63	
R22	Subsumes Arg1:T60 Arg2:T62	
*	OR T70 T71
*	OR T73 T72
R23	Has_index Arg1:T32 Arg2:T33	
T1	Condition 0 15	Hemochromatosis
T2	Condition 17 30	iron overload
T3	Measurement 43 47	TSAT
T4	Value 48 53	> 45%
T5	Condition 61 77	hypersensitivity
T6	Drug 81 91	FerinjectÂ®
T7	Measurement 118 121	CRP
T8	Value 121 129	>20 mg/L
T9	Condition 100 116	active infection
T10	Qualifier 131 153	clinically significant
T11	Condition 154 162	bleeding
T12	Qualifier 164 170	active
T13	Condition 171 181	malignancy
T14	Condition 184 205	Chronic liver disease
T15	Measurement 223 249	alanine transaminase (ALT)
T16	Measurement 253 281	aspartate transaminase (AST)
T17	Value 282 335	above three times the upper limit of the normal range
T19	Procedure 338 363	Immunosuppressive therapy
T20	Condition 367 381	renal dialysis
T21	Mood 383 390	current
T22	Mood 394 401	planned
T23	Temporal 402 426	within the next 6 months
T24	Reference_point 409 426	the next 6 months
T27	Drug 441 455	erythropoietin
T28	Procedure 466 483	oral iron therapy
T29	Procedure 489 506	blood transfusion
T30	Temporal 507 527	in previous 12 weeks
T31	Mood 548 555	planned
T32	Temporal 556 580	within the next 6 months
T33	Reference_point 563 580	the next 6 months
T34	Procedure 457 462;471 483	i. v. iron therapy
T37	Condition 583 607	Unstable angina pectoris
T38	Qualifier 639 661	clinically significant
T39	Condition 674 690	valvular disease
T40	Condition 694 730	left ventricular outflow obstruction
T41	Condition 732 758	obstructive cardiomyopathy
T42	Qualifier 760 777	poorly controlled
T43	Condition 778 802	fast atrial fibrillation
T44	Condition 778 789;806 813	fast atrial flutter
T45	Qualifier 815 832	poorly controlled
T46	Qualifier 833 844	symptomatic
T47	Condition 855 871	tachyarrhythmias
T48	Condition 845 851	brady-
T51	Condition 874 901	Acute myocardial infarction
T52	Condition 905 928	acute coronary syndrome
T53	Condition 930 955	transient ischemic attack
T54	Condition 959 965	stroke
T55	Temporal 966 990	within the last 3 months
T56	Reference_point 973 990	the last 3 months
T58	Procedure 993 1021	Coronary-artery bypass graft
T59	Procedure 1023 1048	percutaneous intervention
T60	Procedure 1126 1139	major surgery
T61	Procedure 1164 1179	cardiac surgery
T62	Procedure 1151 1159;1172 1179	thoracic surgery
T63	Temporal 1181 1205	within the last 3 months
T64	Reference_point 1188 1205	the last 3 months
T66	Non-query-able 1208 1248	Participation in a CHF training program.
T67	Condition 1250 1259	Known HIV
T68	Condition 1260 1264	AIDS
T69	Post-eligibility 1267 1358	Inability to fully comprehend and/or perform study procedures in the investigator's opinion
T70	Condition 1361 1372;1393 1403	Vitamin B12 deficiency
T71	Condition 1380 1403	serum folate deficiency
T72	Condition 1501 1510	lactation
T73	Condition 1488 1497	Pregnancy
T74	Procedure 1647 1662	Anticoagulation
T75	Post-eligibility 1513 1645	Participation in another clinical trial within previous 30 days and/or anticipated participation in another trial during this study.
